# Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes

> **NCT03906695** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Lower-risk Myelodysplastic

## Interventions

- **DRUG:** ASTX727
- **DRUG:** ASTX727
- **DRUG:** ASTX727
- **DRUG:** ASTX727
- **DRUG:** ASTX727

## Key facts

- **NCT ID:** NCT03906695
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-15
- **Primary completion:** 2026-01-31
- **Final completion:** 2026-01-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03906695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03906695, "Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03906695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*